Regression model for analysing time to first clinical relapse
| Time to first relapse | HR | 95% CI | P value |
| Sex (male (57) vs female (113; ref.)) | 0.707 | 0.415 to 1.206 | 0.203 |
| Age (<34 years (84; ref.) vs ≥34 years (86)) | 1.201 | 0.729 to 1.981 | 0.472 |
| Annualised relapse rate at baseline | 1.460 | 1.098 to 1.940 | 0.009 |
| Baseline-EDSS | 1.004 | 0.805 to 1.252 | 0.973 |
| Disease duration since onset (yrs) | 0.945 | 0.891 to 1.003 | 0.062 |
| Last previous DMT (naïve=ref. (35)) basic (52) | 0.930 | 0.410 to 2.110 | 0.983 |
| NTZs (21) | 2.732 | 1.138 to 6.560 | 0.025 |
| NTZa (29) | 3.888 | 1.375 to 10.990 | 0.010 |
| FTY (33) | 5.420 | 2.520 to 11.660 | <0.001 |
Results from our Cox proportional hazard model using an enter method to integrate all the covariates in the final analysis. For analysis of age as a covariate, we split our group according to the median. Reference categories are indicated for categorical covariates. Numbers in brackets in the first column indicate sample numbers for the respective covariate.
Bold values indicate p-values below 0.05
DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; FTY, fingolimod; NTZa, natalizumab (previously active); NTZs, natalizumab (active subgroup).